SNT 8.33% 3.9¢ syntara limited

SNT - Research & Valuation, page-4

  1. 7,149 Posts.
    lightbulb Created with Sketch. 1832
    What MST could have clarified is that there are 2 MDS trials running:
    a. Phase 1c/2 study in low risk MDS in Australia funded by Syntara
    b. Phase 1b/2 study in high risk MDS & CMML in Germany fully funded ($2.5Mn) by the German research group with only our drug being sponsored by Syntara. 7 specialist sites willing to join this trial.

    This would make the investment case look even better IMHO.

    Who doesn’t like a 6X upside thesis?
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.